Identifying biomarkers for lung transplant dysfunction
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
This study is trying to find specific markers in the body that can help doctors understand and manage problems after lung transplants for patients at Foch Hospital.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 900 (estimated) |
| Ages | 15 Years and up |
| Sex | All |
| Sponsor | Hopital Foch Academic / other |
| Locations | 1 site (Suresnes) |
| Trial ID | NCT04837339 on ClinicalTrials.gov |
What this trial studies
This study aims to identify diagnostic and prognostic biomarkers associated with lung transplant dysfunction, which is a significant cause of morbidity and mortality in lung transplant recipients. By collecting biological samples from patients undergoing lung transplantation or being followed post-transplant at Foch Hospital, the study will analyze the underlying mechanisms of transplant rejection and failure. The research focuses on understanding the pathophysiological processes through transcriptomics, gene polymorphisms, and cell phenotyping, which will be contextualized with clinical data. This comprehensive approach seeks to improve early diagnosis and management of lung transplant complications.
Who should consider this trial
Good fit: Ideal candidates include men and women over 15 years old who are scheduled for a lung transplant or are being monitored post-transplant at Foch Hospital.
Not a fit: Patients who are pregnant, have severe anemia, or are unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic tools and treatment strategies for lung transplant recipients, potentially enhancing their long-term survival.
How similar studies have performed: While lung transplantation has been extensively studied, the specific focus on identifying biomarkers for dysfunction is a novel approach that has not been widely tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men or women over 15 years of age * Suffering from a lung condition requiring a transplant planned at Foch Hospital or being followed up at Foch Hospital following a lung transplant * Have signed the informed consent form and for patients aged 15 to 18 years that the person(s) exercising parental authority has/have signed the informed consent. * Be affiliated with a Health Insurance plan. Exclusion Criteria: * Pregnant, parturient and/or lactating woman * Hemoglobin level less than or equal to 8g/dl * Persons of full age who are subject to a legal protection measure or who are unable to express their consent * Persons under the protection of justice * Not being able to follow the study requirements for geographical, social or psychological reasons * Patient refusal.
Where this trial is running
Suresnes
- Roux — Suresnes, France (Recruiting)
Study contacts
- Study coordinator: Antoine ROUX, Dr
- Email: a.roux@hopital-foch.com
- Phone: 0146252635
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.